drugset / Trial / NCT07314723
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW2821 | Monoclonal antibody | 1.25 mg/kg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |